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Benzothiazole Thioflavin T improves obesity-related 
symptoms in mice
abstract
Background and Purposes: In order to counteract the obesity epidem-
ics, novel therapeutics are needed. Thioflavin T (ThT) is a benzothiazole 
used as an amyloid probe and has other properties such as anti-aging and 
antihyperglycemic effects. The current study aimed at investigating its effect 
on obesity.
Materials and Methods: A mouse model of obesity was generated by 
feeding male NMRI mice with a high fat diet (HFD) for 8 weeks. After this 
period, mice diet was switched to normal rodent diet, and ThT was orally 
administered with a 12 mg/Kg dose. The treatment effect was assessed on 
biochemical parameters, adipokines (adiponectin and leptin), total anti-
oxidant capacity and TNF-a. Histological investigation was made on 
samples taken from adipose tissue and liver.
Results and Conclusion: After receiving HFD, mice exhibited sig-
nificantly increased body weight compared with a control group as well as 
well as abnormality in biochemical parameters. A significantly effective 
result was obtained on body weight, blood glucose, cholesterol and ALT se-
rum levels which decreased in the treated group. ThT caused also a signifi-
cant decrease in leptin levels and TNF-a. Furthermore, the compound led 
to a reduction in the size of adipose tissue cells, as well as the number of 
lipid droplets in hepatic tissue. In conclusion, it is suggested that ThT possess 
an interesting potential for being used as an anti-obesity drug, especially 




Obesity is associated with multiple issues such as type 2 diabetes and cardiovascular diseases (1) (2), is a component of metabolic syndro-
me, could affect intellectual performance (3), causes psychological disor-
ders (4) and finally become life-threatening (5). An inflammatory compo-
nent is also present, which has been related to the release of free fatty acids 
and inflammatory cytokines from the adipose tissue and could predispose 
to different pathologies including cancer (6). Obesity has a high preva-
lence, which has led to the use of the „epidemics” term, and a simple ef-
ficient remedy is still lacking (7). Previously used antiobesity drugs, such 
as orlistat and sibutramine, had modest clinical efficacy and serious side 
effects(8), while the newly approved drugs have still limited effect and 
may also need to be used alongside with lifestyle modification (9).
With regard to the necessity of finding compounds that could be 
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that had shown the beneficial effect of thioflavin T (ThT) 
in an animal model of diabetes (10), the present study was 
designed in order to test the effect of ThT in mice fed with 
a high fat diet. Thioflavin T is a benzothiazole that has 
been widely used to characterize amyloid fibrils, which 
are ordered aggregated protein structures related to a va-
riety of diseases (11).
materIals and methods
animals
Male NMRI mice(six weeks old) weighing 25 ±5 g 
were obtained from the Razi Vaccine and Serum Institute, 
Karaj, Iran. Mice were exposed to a12-h light/dark cycle 
and the animal room had a constant temperature of 25 
°C. Mice were housed in the animal room in standard 
cages and allowed to adapt at for one week, after which 
they were randomly divided into two groups (n = 12 in 
the control group and n=24 in the obese group). The con-
trol group was receiving standard rodent diet the obese 
group was receiving high-fat diet for eight weeks. The 
high-fat diet was prepared from a mix of 15 g of mouse 
pellet standard chow, 10 g of roasted ground nut, 10 g of 
milk chocolate and 5 g of sesame crackers. 20 g roasted 
sesame was added to ten-fold of these components, result-
ing into 18 kJ/g energy content, and the obese group was 
fed 240g creamy biscuits (3644 kJ) weekly. The normal 
group was allowed ad libitum access to standard chow, 
taking a total of 13kJ/g weekly (12). After eight weeks, all 
animals were given standard rodent diet, and the obese 
animals were divided into two groups: control obese and 
experimental group. The experimental group was treated 
with ThT (12mg/kg/day) by oral gavage for eight weeks; 
ThT was dissolved in distilled water, and the dose was 
chosen based on previous results obtained in diabetic 
animals (10). The obese control group did not received 
any treatment Mice were weighed weekly during the 8 
weeks of treatment. At the end of the experiment, the 
animals were anesthetized and sacrificed; blood samples 
were collected and immediately centrifuged at 1500g for 
10 min at 4 °C. Serums were then collected and stored at 
4 °C until further analyzes were made. The experimental 
protocol was approved by the Research and Ethics Com-
mittee of the Endocrinology and Metabolism Research 
Institute (EMRI) of Tehran University of Medical Sci-
ences (code: EC-00245)in accordance with the interna-
tional guidelines set out in the Guide for the Care and 
Use of Laboratory Animals (Institute of Laboratory Ani-
mal Resources, 1996).
Biochemical parameters
Serum levels of total cholesterol, triglyceride, HDL, 
ALT and AST were measured with the use of enzymatic 
methods (Pars Azmoon, Iran).Blood glucose levels were 
measured by a glucometer apparatus (ACCU-CHEK, 
Germany).Plasma adiponectin‚ TNF-a and leptin con-
centration were determined by ELISA (respectively R&D 
Systems, USA; Enzo life Science, USA and ALPCO,USA). 
Plasma total antioxidant capacity (TAC) levels were mea-
sured by a colorimetric method (BioVision,USA).
Fig. 1 A. Effect of receiving standard diet (control group) and high-fat diet (obese group) on mice body weight. W is the abbreviation used for 
„week”. ***p < 0.001 (compared within the same group, and with the second week). B. Effects of ThT treatment on body weight of obese mice. 
*p < 0.05 : compared with W1 and W2; **p < 0.01: compared with W1, W2 and W3;*** p < 0.001 : compared with W1, W2 and W3. C. 
Control and untreated obese group mice weight changes during the second part of the experiment. This graph reports the same time period as 
Fig.1b. In all instances, data is shown as mean ± SD.
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histological studies
Sample abdominal adipose tissue samples were taken 
and fixed in formalin and subsequently stained with he-
matoxylin and eosin (H&E).
statistical analysis
The data were statistically analyzed by SPSS, with the 
use of ANOVA and Tukey’s test. Values  are reported as 
mean± SD and the level of significance set at p < 0.05.
results
Body weight and blood glucose
Mice that were receiving high-fat diet gained more 
weight than the control group, and the difference was 
clearly significant from the 4th week onward (Fig.1a). 
Treating these mice (termed „obese”) with ThT resulted 
in a marked weight loss (Fig.1b), while at the same period, 
the untreated obese and the control group mice did not 
show any significant weight change (Fig. 1c).
The high-fat diet resulted into elevated blood glucose 
levels in mice compared to the control group (Table 1). In 
the eighth week of treatment‚ ThT-treated mice showed 
significantly lower levels of blood glucose (p < 0.05) in 
comparison with obese and control groups at week 8 of 
the experiment.
alt and ast
At the end of the experiment (16 weeks), AST and ALT 
levels were measured. In the untreated obese group, only 
Table 1. Effects of ThT treatment on blood glucose (mg/dl) levels in 
mice at the start of the experiment (week 0), and at weeks 4 and 8. 
Data is shown as mean±SD. *p<0.05, obtained by comparing ThT-
treated and obese groups. 









Control 112.66 ± 11.56 141 ± 2.08 166 ± 3.60
Obese 185 ± 30.17 152.66 ± 3.17 165.33 ± 12.25
ThT 154.33 ± 4.48 126 ± 16.56 113 ± 11.84*
Figure 2. AST (a) and ALT (b) levels in the control, untreated obese, and ThT-treated mice (shown as Thioflavin-T in the graph). Data is shown 
as mean ± SD. #p < 0.05 compared with the control group. * p < 0.05 compared with the untreated obese group.
Figure 3. Adiponectin (a) and leptin (b) levels in the control, untreated obese, and ThT-treated mice (shown as Thioflavin-T in the graph). Data 
is shown as mean ± SD. &&p < 0.001 compared with the control group; ** p < 0.001compared with the untreated obese group.
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of the treated obese group (Fig.4B and C), but not in 
triglyceride levels (Fig.4A).
tac and tnf-a
Total antioxidant capacity did not change significant-
ly in the untreated obese mice compared with the control 
group, and ThT administration had no significant effect 
on this parameter either (p > 0.05, results not shown). It 
should be pointed out that the gavage procedure is stress-
the increase of ALT levels was significant in comparison 
with the control group (Fig. 2). Upon treatment with ThT, 
ALT levels were significantly decreased (p<0.05, Fig. 2b).
adipokines
In comparison with the control group, the untreated 
obese mice showed no significant change in adiponectin 
levels, while there was a significant increase in their leptin 
levels (p < 0.001) (Fig.3a and b). Upon eight-week admin-
istration of ThT, adiponectin levels changes were not sig-
nificant compared with obese mice (p > 0.05), (Fig. 3a). 
On the other hand, ThT was able to significantly lower 
leptin concentrations compared to the untreated obese 
group (p < 0.001) (Fig.3b).
lipids
The serum triglyceride (TG) and cholesterol levels of 
the untreated obese group were found to be significantly 
higher compared with the control group (p < 0.05, and p 
< 0.01 respectively), while HDL levels were significantly 
lower (p < 0.05) (Fig.4). ThT treatment had a significant 
effect in lowering cholesterol and increasing HDL levels 
Figure 4. Serum triglycerides(a), cholesterol (b) and HDL (c) levels in the control, untreated obese, and ThT-treated mice (shown as Thioflavin-T 
in the graph). Data is shown as mean ± SD. (a): * p < 0.05 compared with the control group; (b): ## p < 0.01 compared with the control 
group.** p < 0.01 compared with the obese group;(c): # p < 0.05 compared with the control group.* p < 0.05 compared with the control group.
Figure 5. Serum TNF-a levels in the control, untreated obese, and 
ThT-treated mice (shown as Thioflavin-T in the graph). Data is 
shown as mean ± SD. ** p < 0.01 compared with the obese group.
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ful and may affect antioxidant levels, and to obtain more 
accurate results, a comparison with an untreated group is 
needed which would receive a placebo by gavage.
Finally, the TNF-a inflammatory factor could be sig-
nificantly decreased upon treatment with ThT (Fig. 5).
histological studies
adipocytes
Compared with the control group, the untreated obese 
mice show lager adipocytes (p < 0.0001) (Fig.6), while 
upon treatment with ThT, adipose cells diameter is sig-
nificantly reduced compared with the untreated group (p 
< 0.0001).
hepatocytes
The result of Hematoxylin- Eosin (H&E) staining of 
the mice hepatocytes is shown in Fig.7 a-c. Obese animals 
show lipid droplets and multinucleate cells and the overall 
structure appears to be disordered in comparison with 
healthy animals. Treatment with ThT has a beneficial effect 
on liver cells and is also able to reduce the lipid droplets.
dIscussIon
Consumption of a high fat diet results in the disrup-
tion of the normal lipid profile, as well as hyperglycemia 
and increase of cytokines that would contribute to an 
inflammatory state (13). Appearance of a fatty liver that 
is infiltrated by macrophages is another deleterious con-
sequence that could be mimicked in animal models with 
the use of palatable food that leads to the animals hyper-
phagia (14). A similar state was observed in our high fat 
fed model, where accordingly, a higher weight gain had 
occurred, as well as abnormality in related biochemical 
parameters and adipokines.
Thioflavin T is a benzothiazole dye that is widely used 
as a mean to characterize amyloid structures; it is pro-
posed to exert its effect by binding to cavities found in the 
fibrils structures (15), but has also been observed to have 
the potential for making more specific interactions with 
amyloid forming proteins precursors (16), as well as albu-
min (17). These recent findings are suggestive of the po-
tential of ThT as a ligand which may act via specific in-
teractions with macromolecular targets.
In the current study, ThT was shown to reduce the 
body weight of high-fat fed animals, correct their lipid 
profile, and lower their blood glucose levels. In a previous 
study on diabetic rats, similar effects had been observed 
(10). Since ThT-treated animals showed lower levels of 
serum alpha-amylase, and a slight in vitro inhibitory effect 
had also been observed for ThT toward alpha-amylase 
enzyme (10), the current findings on blood glucose levels 
and weight may be partly attributed to this property of 
ThT. In fact, glucosidase inhibitors may be beneficial in 
the „diabesity” state, by lowering postprandial glucose 
levels (18, 19) and helping in weight loss (20, 21). Alpha-
amylase inhibitors have been observed to positively affect 
disturbed lipid profiles too (22). ThT is also hypothesized 
to have an appetite suppressing effect (10).
Liver function markers AST and ALT that were altered 
as a result of high fat diet consumption in mice were de-
creased upon treatment with ThT, and accordingly, liver 
tissue disruption and accumulation of fat droplets in he-
patocytes was also ameliorated by the compound. It is 
interesting to mention that reports on acarbose (a gluco-
sidase inhibitor) have shown its potential in the treatment 
of hepatosteatosis (23). The benzothiazole core has been 
used as a starting point to synthesize various derivatives 
with diverse biological properties including antitumor, 
Figure 6. Mean diameter of adipocytes taken from abdominal adi-
pose tissue in control, untreated obese, and ThT-treated mice; data 
is shown as the mean ± SD, and ###p < 0.0001 compared with 
the obese group;*** p < 0.0001 compared with the obese group.
Figure 7. Representative H&E stained sections of liver tissue from control (a), obese (b), and ThT-treated group. Arrows point to fat droplets.
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antimicrobial, antihelmintic, antioxidant, and anti-in-
flammatory ones (24). These derivatives, which show a 
variety of structures, act on a range of different targets, 
including enzymes that may be of importance in a par-
ticular disease. As an example, the anti-inflammatory 
activity of benzothiazoles could be related to their prop-
erty as inhibitors of cyclooxygenase and lipooxygenase 
enzymes (25, 26). In the current study, ThT has been 
observed to have antioxidant and antinflammatory prop-
erties to some extent, and further act on the adipose tissue 
too. The significant effect of ThT on leptin is specially of 
interest, with regard to the importance of this adipokine 
in weight regulation (27). Recently proposed antiobesity 
compounds that act on accumulation of visceral fat have 
also been observed to influence leptin levels (28), (29), 
(30).
conclusIons
Thioflavin T, the benzothiazole dye that is widely used 
for its ability to interact with amyloid fibrils, has been 
shown to possess an antiobesity potential. High fat-fed 
mice that were treated with ThT underwent weight loss, 
change in adipocyte size and decrease in liver accumu-
lated fat, that were accompanied with a correction of 
blood glucose levels and lipid profile. Furthermore, ThT 
effect comprised an antioxidant and anti-inflammatory 
component, alongside with a regulation of adipokine lev-
els. With regard to the potential of benzothiazoles to exert 
various biological roles, it is suggested that ThT could be 
considered as a candidate core compound against diabetes 
and obesity, whose derivatives may be worth of study in 
these pathologic conditions.
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